Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

KURA Feb 16 '24 17.50 Call

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [N/A]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ rootItem.symbol ]]underlying price [[ rootItem.lastPrice ]] [[ rootItem.priceChange ]] ([[ rootItem.percentChange ]]) [[ rootItem.tradeTime ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML GlobeNewswire - Mon Dec 8, 9:30AM CST

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS  – Median duration of complete response...

KURA : 10.46 (-2.61%)
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia GlobeNewswire - Wed Dec 3, 7:32AM CST

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 10.46 (-2.61%)
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin GlobeNewswire - Tue Dec 2, 7:02AM CST

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

KURA : 10.46 (-2.61%)
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML) GlobeNewswire - Tue Nov 25, 4:16PM CST

SAN DIEGO and TOKYO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced KOMZIFTI™ (ziftomenib),...

KURA : 10.46 (-2.61%)
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia GlobeNewswire - Thu Nov 13, 9:51AM CST

– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1 -mutated AML defined by historically poor outcomes and low...

KURA : 10.46 (-2.61%)
Kura Oncology to Participate in Upcoming Investor Conference GlobeNewswire - Wed Nov 12, 3:05PM CST

SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 10.46 (-2.61%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Nov 7, 6:30AM CST

SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...

KURA : 10.46 (-2.61%)
Kura Oncology: Q3 Earnings Snapshot AP - Tue Nov 4, 5:50AM CST

Kura Oncology: Q3 Earnings Snapshot

KURA : 10.46 (-2.61%)
Kura Oncology Reports Third Quarter 2025 Financial Results GlobeNewswire - Tue Nov 4, 5:31AM CST

– New Drug Application for ziftomenib in adults with R/R NPM1 -m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate...

KURA : 10.46 (-2.61%)
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin GlobeNewswire - Mon Nov 3, 3:02PM CST

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 10.46 (-2.61%)
More news for this symbol

KURA Related stocks

Symbol Latest 3M %Chg
KURA 10.46 +18.53%
Kura Oncology
AZN 90.29 +11.33%
Astrazeneca Plc ADR
AMGN 317.38 +12.26%
Amgen Inc
GILD 123.21 +4.54%
Gilead Sciences Inc
VRTX 445.93 +12.22%
Vertex Pharmaceutic
BMY 51.20 +7.70%
Bristol-Myers Squibb Company

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot